AbbVie Q2: Immunology on Track, Apogee Deal Tweaks Guidance

What happened

AbbVie’s Q2 revenue reached $16.99B, driven by 15% immunology growth as Skyrizi ($5.51B) and Rinvoq ($2.53B) tracked toward full-year targets, while Humira erosion continued. Neuroscience surged 20%, but aesthetics were flat with Juvederm still soft and oncology down slightly. The company announced the acquisition of Apogee Therapeutics to deepen its immunology pipeline, which led to a modest $0.04 cut at the midpoint of adjusted EPS guidance to $13.87–$14.07. The quarter confirms demand-led momentum in the core franchise, but the deal introduces near-term dilution and integration risk.

Implication

The immunology beat supports the 2026 revenue framework, yet the Apogee acquisition adds $0.14 of dilution and execution uncertainty, while aesthetics remains a drag without clear recovery. The updated EPS guidance reflects ongoing pipeline investment headwinds, and investors should monitor Juvederm trends and Rinvoq payer dynamics. The thesis hangs on sustained demand-led growth; until aesthetics stabilizes and the acquisition closes, a cautious stance is warranted.

Thesis delta

The quarter validates the demand-driven immunology narrative, reducing downside risk but not yet warranting an upgrade. The Apogee deal deepens the pipeline at the cost of near-term earnings, adding integration uncertainty. The WAIT rating holds; confirmation of aesthetics stabilization and Rinvoq's access trajectory remain prerequisites for a more constructive view.